Abstract | PURPOSE: MATERIALS AND METHODS: As part of the Medical Therapy of Prostatic Symptoms (MTOPS) clinical trial, which demonstrated the effectiveness of combination drug therapy in slowing benign prostatic hyperplasia progression, an archive of biological specimens linked to clinical data was collected for future profiling of disease pathology and changes associated with response to drug therapy. The MTOPS Prostatic Samples Analysis ( MPSA) Consortium was established to identify and validate molecular markers that may better define benign prostatic hyperplasia related pathologies, identify risk of progression of lower urinary tract symptoms, and predict response to drug therapy using the MTOPS archive. The cooperating MPSA Biomarker Discovery Sites and Pathology Coordinating Center use diverse methodologies and scientific approaches as well as unique expertise to address the goals of the Consortium. RESULTS: CONCLUSIONS: These findings and ongoing Consortium discovery efforts have the potential to provide a greater understanding of the defects underlying disease pathology, and may lead to the development of early and more effective pharmacological treatment strategies for benign prostatic hyperplasia.
|
Authors | Chris Mullins, M Scott Lucia, Simon W Hayward, Jeannette Y Lee, Jonathan M Levitt, Victor K Lin, Brian C-S Liu, Arul M Chinnaiyan, Mark A Rubin, Kevin Slawin, Robert A Star, Robert H Getzenberg, MPSA Consortium |
Journal | The Journal of urology
(J Urol)
Vol. 179
Issue 4
Pg. 1243-56
(Apr 2008)
ISSN: 1527-3792 [Electronic] United States |
PMID | 18280515
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Biomarkers
(blood)
- Humans
- Male
- Middle Aged
- Prostatic Hyperplasia
(blood, diagnosis, drug therapy, genetics)
|